MIRATI THERAPEUTICS INC's ticker is MRTX and the CUSIP is 60468T105. A total of 247 filers reported holding MIRATI THERAPEUTICS INC in Q3 2021. The put-call ratio across all filers is 0.35 and the average weighting 0.7%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $2,614,000 | +20.6% | 60,000 | 0.0% | 0.00% | +50.0% |
| Q2 2023 | $2,168,000 | -2.8% | 60,000 | 0.0% | 0.00% | -33.3% |
| Q1 2023 | $2,231,000 | -17.9% | 60,000 | 0.0% | 0.00% | 0.0% |
| Q4 2022 | $2,719,000 | -36.2% | 60,000 | -1.1% | 0.00% | -40.0% |
| Q3 2022 | $4,264,000 | +4.0% | 60,638 | -0.7% | 0.01% | 0.0% |
| Q2 2022 | $4,099,000 | -28.9% | 61,055 | -12.9% | 0.01% | +25.0% |
| Q1 2022 | $5,764,000 | -43.7% | 70,098 | +0.4% | 0.00% | -55.6% |
| Q4 2021 | $10,241,000 | -16.8% | 69,810 | +0.3% | 0.01% | -10.0% |
| Q3 2021 | $12,313,000 | +5.4% | 69,598 | -3.8% | 0.01% | 0.0% |
| Q2 2021 | $11,682,000 | -16.6% | 72,323 | -11.6% | 0.01% | -50.0% |
| Q1 2021 | $14,008,000 | -32.2% | 81,774 | -13.0% | 0.02% | -33.3% |
| Q4 2020 | $20,648,000 | +3.8% | 94,008 | -21.5% | 0.03% | -11.8% |
| Q3 2020 | $19,892,000 | -5.9% | 119,795 | -35.3% | 0.03% | -5.6% |
| Q2 2020 | $21,141,000 | +54.3% | 185,171 | +3.9% | 0.04% | +28.6% |
| Q1 2020 | $13,704,000 | -40.3% | 178,271 | 0.0% | 0.03% | -15.2% |
| Q4 2019 | $22,972,000 | +25.0% | 178,271 | -24.4% | 0.03% | +6.5% |
| Q3 2019 | $18,381,000 | -73.4% | 235,930 | -64.8% | 0.03% | -20.5% |
| Q2 2019 | $69,102,000 | +321.6% | 670,890 | +200.0% | 0.04% | +39.3% |
| Q1 2019 | $16,392,000 | +72.8% | 223,630 | 0.0% | 0.03% | +55.6% |
| Q4 2018 | $9,486,000 | -9.9% | 223,630 | 0.0% | 0.02% | +5.9% |
| Q3 2018 | $10,533,000 | -5.1% | 223,630 | -0.7% | 0.02% | -10.5% |
| Q2 2018 | $11,099,000 | +61.7% | 225,130 | +0.7% | 0.02% | +46.2% |
| Q1 2018 | $6,865,000 | +366.7% | 223,630 | +177.5% | 0.01% | +333.3% |
| Q4 2017 | $1,471,000 | +57.2% | 80,600 | +0.8% | 0.00% | +50.0% |
| Q3 2017 | $936,000 | +220.5% | 80,000 | 0.0% | 0.00% | +100.0% |
| Q2 2017 | $292,000 | -29.8% | 80,000 | 0.0% | 0.00% | 0.0% |
| Q1 2017 | $416,000 | +9.5% | 80,000 | 0.0% | 0.00% | 0.0% |
| Q4 2016 | $380,000 | -28.2% | 80,000 | 0.0% | 0.00% | 0.0% |
| Q3 2016 | $529,000 | -39.5% | 80,000 | -50.0% | 0.00% | 0.0% |
| Q2 2016 | $874,000 | – | 160,000 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Aviva Holdings Ltd. | 3,135,966 | $116,595,216 | 81.37% |
| ORACLE INVESTMENT MANAGEMENT INC | 201,400 | $7,488,052 | 7.25% |
| Paradigm Biocapital Advisors LP | 1,396,779 | $51,932,243 | 4.92% |
| Octagon Capital Advisors LP | 750,000 | $27,885,000 | 4.01% |
| Boxer Capital, LLC | 2,000,000 | $74,360 | 3.65% |
| Artal Group S.A. | 1,537,709 | $57,172 | 3.40% |
| Avoro Capital Advisors LLC | 5,555,555 | $206,555,535 | 3.06% |
| RTW INVESTMENTS, LP | 3,643,114 | $135,450,979 | 2.82% |
| INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 244,000 | $9,071,920 | 2.53% |
| Kynam Capital Management, LP | 499,853 | $18,584,535 | 2.40% |